P. Agrawal, K. Yu, A. R. Salomon, and J. M. Sedivy, Proteomic profiling of Myc-associated proteins, Cell Cycle, vol.9, pp.4908-4921, 2010.

M. L. Berres, R. R. Koenen, A. Rueland, M. M. Zaldivar, D. Heinrichs et al., Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice, J. Clin. Invest, vol.120, pp.4129-4140, 2010.

P. Burra and K. I. Rodriguez-castro, Neoplastic disease after liver transplantation: focus on de novo neoplasms, World J. Gastroenterol, vol.21, pp.8753-8768, 2015.

E. E. Calle, C. Rodriguez, K. Walker-thurmond, and M. J. Thun, , 2003.

, N. Engl. J. Med, vol.348, pp.1625-1638

D. F. Calvisi, S. Ladu, F. Pinna, M. Frau, M. L. Tomasi et al., SKP2 and CKS1 promote degradation of cell cycle regulators and are associated with hepatocellular carcinoma prognosis, Gastroenterology, vol.137, pp.1816-1826, 2009.

R. T. Chung and T. F. Baumert, Curing chronic hepatitis C-the arc of a medical triumph, N. Engl. J. Med, vol.370, pp.1576-1578, 2014.

A. B. Cooper, J. Wu, D. Lu, and M. A. Maluccio, Is autotaxin (ENPP2) the link between hepatitis C and hepatocellular cancer?, J. Gastrointest. Surg, vol.11, pp.1634-1639, 2007.

J. Cuzick, I. Sestak, J. F. Forbes, M. Dowsett, J. Knox et al., , 2014.

, Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebocontrolled trial, Lancet, vol.383, pp.1041-1048

J. A. Davila, R. O. Morgan, P. A. Richardson, X. L. Du, K. A. Mcglynn et al., Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States, Hepatology, vol.52, pp.132-141, 2010.

R. A. Fisher, Statistical Methods for Research Workers, 1932.

A. Forner, J. M. Llovet, and J. Bruix, Hepatocellular carcinoma, Lancet, vol.379, pp.1245-1255, 2012.
URL : https://hal.archives-ouvertes.fr/hal-01134844

B. Franssen, K. Alshebeeb, P. Tabrizian, J. Marti, E. S. Pierobon et al., Differences in surgical outcomes between hepatitis B-and hepatitis C-related hepatocellular carcinoma: a retrospective analysis of a single North American center, Ann. Surg, vol.260, pp.650-658, 2014.

B. C. Fuchs, Y. Hoshida, T. Fujii, L. Wei, S. Yamada et al., Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma, Hepatology, vol.59, pp.1577-1590, 2014.

S. Gordon, G. Akopyan, H. Garban, and B. Bonavida, Transcription factor YY1: structure, function, and therapeutic implications in cancer biology, Oncogene, vol.25, pp.1125-1142, 2006.

Y. Hoshida, A. Villanueva, M. Kobayashi, J. Peix, D. Y. Chiang et al., Gene expression in fixed tissues and outcome in hepatocellular carcinoma, N. Engl. J. Med, vol.359, 1995.

Y. Hoshida, A. Villanueva, A. Sangiovanni, M. Sole, C. Hur et al., Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis, Gastroenterology, vol.144, pp.1024-1030, 2013.

Y. Hoshida, B. C. Fuchs, N. Bardeesy, T. F. Baumert, C. et al., , 2014.

, Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma, J. Hepatol, vol.61, pp.79-90

G. Huang and D. R. Brigstock, Regulation of hepatic stellate cells by connective tissue growth factor, Front Biosci, vol.17, pp.2495-2507, 2012.

K. Ishak, A. Baptista, L. Bianchi, F. Callea, J. De-groote et al., Histological grading and staging of chronic hepatitis, J. Hepatol, vol.22, pp.696-699, 1995.

S. H. Itzkowitz and D. H. Present, Consensus conference: colorectal cancer screening and surveillance in inflammatory bowel disease, Inflamm. Bowel Dis, vol.11, pp.314-321, 2005.

N. Kawada, K. Imanaka, T. Kawaguchi, C. Tamai, R. Ishihara et al., Hepatocellular carcinoma arising from non-cirrhotic nonalcoholic steatohepatitis, J. Gastroenterol, vol.44, pp.1190-1194, 2009.

Y. Kihara, H. Mizuno, C. , and J. , Lysophospholipid receptors in drug discovery, Exp. Cell Res, vol.333, pp.171-177, 2015.

L. Y. King, C. Canasto-chibuque, K. B. Johnson, S. Yip, X. Chen et al., A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration, Gut, vol.64, pp.1296-1302, 2015.

S. M. Lippman, E. A. Klein, P. J. Goodman, M. S. Lucia, I. M. Thompson et al., Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT), JAMA, vol.301, pp.39-51, 2009.

W. Z. Mehal and D. Schuppan, Antifibrotic therapies in the liver, Semin. Liver Dis, vol.35, pp.184-198, 2015.

T. Minami, R. Tateishi, S. Shiina, R. Nakagomi, M. Kondo et al., Comparison of improved prognosis between hepatitis B-and hepatitis C-related hepatocellular carcinoma, Hepatol. Res, vol.45, pp.99-107, 2015.

R. L. Morgan, B. Baack, B. D. Smith, A. Yartel, M. Pitasi et al., Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies, Ann. Intern. Med, vol.158, pp.329-337, 2013.

K. Muir, A. Hazim, Y. He, M. Peyressatre, D. Y. Kim et al., Proteomic and lipidomic signatures of lipid metabolism in NASH-associated hepatocellular carcinoma, Cancer Res, vol.73, pp.4722-4731, 2013.

H. Nakagawa, H. Ikeda, K. Nakamura, R. Ohkawa, R. Masuzaki et al., Autotaxin as a novel serum marker of liver fibrosis, Clin. Chim. Acta, vol.412, pp.1201-1206, 2011.

J. P. Pradere, J. Klein, S. Gres, C. Guigne, E. Neau et al., LPA1 receptor activation promotes renal interstitial fibrosis, J. Am. Soc. Nephrol, vol.18, pp.3110-3118, 2007.
URL : https://hal.archives-ouvertes.fr/inserm-00409718

N. Sakai, J. Chun, J. S. Duffield, T. Wada, A. D. Luster et al., LPA1-induced cytoskeleton reorganization drives fibrosis through CTGF-dependent fibroblast proliferation, FASEB J, vol.27, pp.1830-1846, 2013.

M. K. Saville, A. Sparks, D. P. Xirodimas, J. Wardrop, L. F. Stevenson et al., Regulation of p53 by the ubiquitin-conjugating enzymes UbcH5B/C in vivo, J. Biol. Chem, vol.279, pp.42169-42181, 2004.

W. M. Song and B. Zhang, Multiscale embedded gene Co-expression network analysis, PLoS Comput. Biol, vol.11, 2015.

A. J. Stein, G. Bain, P. Prodanovich, A. M. Santini, J. Darlington et al., , 2015.

, Structural basis for inhibition of human autotaxin by four potent compounds with distinct modes of binding, Mol. Pharmacol, vol.88, pp.982-992

A. Subramanian, P. Tamayo, V. K. Mootha, S. Mukherjee, B. L. Ebert et al., Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles, Proc. Natl. Acad. Sci. USA, vol.102, pp.15545-15550, 2005.

J. S. Swaney, C. Chapman, L. D. Correa, K. J. Stebbins, A. R. Broadhead et al., Pharmacokinetic and pharmacodynamic characterization of an oral lysophosphatidic acid type 1 receptor-selective antagonist, J. Pharmacol. Exp. Ther, vol.336, pp.693-700, 2011.

A. M. Tager, P. Lacamera, B. S. Shea, G. S. Campanella, M. Selman et al., Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis, Nat. Med, vol.14, pp.2584-2593, 2008.

B. Vogelstein, N. Papadopoulos, V. E. Velculescu, S. Zhou, L. A. Diaz et al., Cancer genome landscapes, Science, vol.339, pp.1546-1558, 2013.

N. Watanabe, H. Ikeda, K. Nakamura, R. Ohkawa, Y. Kume et al., Both plasma lysophosphatidic acid and serum autotaxin levels are increased in chronic hepatitis C, J. Clin. Gastroenterol, vol.41, pp.616-623, 2007.

Y. J. Zhang, H. Li, H. C. Wu, J. Shen, L. Wang et al., Silencing of Hint1, a novel tumor suppressor gene, by promoter hypermethylation in hepatocellular carcinoma, Cancer Lett, vol.275, pp.277-284, 2009.

D. Y. Zhang, N. Goossens, J. Guo, M. C. Tsai, H. I. Chou et al., , 2016.

, A hepatic stellate cell gene expression signature associated with outcomes in hepatitis C cirrhosis and hepatocellular carcinoma after curative resection, Gut, vol.65, pp.1754-1764